Evidence map›Paper›PMID 41698954›Full record

Trial reportNature communications2026

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

O Hamid, V Ekström-Rydén, I Mehmi, D Wang, M Patel, S Alsaqal, S Irenaeus, C Nordström, L C Sandin, H Grauers Wiktorin and 5 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

O Hamid *The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Medical Oncology, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8238-4655
V Ekström-Rydén *Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0009-0000-6053-3392
I MehmiThe Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Medical Oncology, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2253-2206
D WangBaylor College of Medicine, McNair Campus, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3341-8652
M PatelBaylor College of Medicine, McNair Campus, Houston, TX, USA.ORCID http://orcid.org/0000-0003-4127-3147
S AlsaqalDepartment of Surgical Sciences, Radiology & Molecular Imaging, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0001-7874-8084
S IrenaeusDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-2107-7512
C NordströmLokon Pharma AB, Uppsala, Sweden.
L C SandinLokon Pharma AB, Uppsala, Sweden.
H Grauers WiktorinDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-4412-5695
T LövgrenDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-2170-0682
E ErikssonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
J Leja-JarbladLokon Pharma AB, Uppsala, Sweden.
A LoskogDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. angelica.loskog@igp.uu.se.ORCID http://orcid.org/0000-0001-8583-6138
G J UllenhagDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-4949-3267

Funding

Barncancerfonden (Swedish Childhood Cancer Foundation) PR2021-0061Cancerfonden (Swedish Cancer Society) 23 2698 Pj HVetenskapsrådet (Swedish Research Council) 2024-03471
6 · The paper itself

Abstract

This phase I/II study evaluated the capacity of tumor microenvironment (TME) gene engineering by intratumoral injection of a viral vector encoding a designed CD40L and 4-1BBL combined with intravenous atezolizumab (anti-PD-L1 antibody) to induce immune activation in 24 patients with stage IV malignant melanoma refractory to PD-1 inhibition. Primary objective was tolerability. Tumor response, pharmacokinetics, and biomarker evaluations were secondary. Treatment was well-tolerated in both dose cohorts (1×10

Indexed as

Antibodies, Monoclonal, HumanizedGenetic EngineeringMelanomaTumor MicroenvironmentAdultAgedCD40 LigandFemaleGenetic VectorsHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedatezolizumabCD40 Ligand

Identifiers

PMID41698954
PMCPMC12913765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.